Phase II Study of Fluconazole for Lymphocutaneous and Visceral Sporotrichosis
|ClinicalTrials.gov Identifier: NCT00004938|
Recruitment Status : Completed
First Posted : February 25, 2000
Last Update Posted : June 9, 2006
I. Evaluate the efficacy of fluconazole in patients with lymphocutaneous or visceral sporotrichosis.
|Condition or disease||Intervention/treatment||Phase|
|Sporotrichosis||Drug: fluconazole||Phase 2|
Patients are treated with daily oral fluconazole for up to 24 months. Follow-up continues for at least 1 year.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||30 participants|
|Study Start Date :||August 1996|
|Estimated Study Completion Date :||August 1996|
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00004938
|Study Chair:||William Dismukes||University of Alabama at Birmingham|